The DOI matches its Crossref record; 133 of the 133 references it cites were found in a registry or an index.
Small molecule inhibitors targeting the EGFR/ErbB family of protein-tyrosine kinases in human cancers
Abstract
The EGFR family is among the most investigated receptor protein-tyrosine kinase groups owing to its general role in signal transduction and in oncogenesis. This family consists of four members that belong to the ErbB lineage of proteins (ErbB1-4). The ErbB proteins function as homo and heterodimers. These receptors contain an extracellular domain that consists of four parts: domains I and III are leucine-rich segments that participate in growth factor binding (except for ErbB2) and domains II and IV contain multiple disulfide bonds. Moreover, domain II participates in both homo and heterodimer formation within the ErbB/HER family of proteins. Seven ligands bind to EGFR including epidermal growth factor and transforming growth factor-α, none bind to ErbB2, two bind to ErbB3, and seven ligands bind to ErbB4. The extracellular domain is followed by a single transmembrane segment of about 25 amino acid residues and an intracellular portion of about 550 amino acid residues that contains (i) a short juxtamembrane segment, (ii) a protein kinase domain, and (iii) a carboxyterminal tail. ErbB2 lacks a known activating ligand and ErbB3 is kinase impaired. Surprisingly, the ErbB2-ErbB3 heterodimer complex is the most active dimer in the family. These receptors are implicated in the pathogenesis of a large proportion of lung and breast cancers, which rank first and second, respectively, in the incidence of all types of cancers (excluding skin) worldwide. On the order of 20% of non-small cell lung cancers bear activating mutations in EGFR. More than 90% of these patients have exon-19 deletions (746ELREA750) or the exon-21 L858R substitution. Gefitinib and erlotinib are orally effective type I reversible EGFR mutant inhibitors; type I inhibitors bind to an active enzyme conformation. Unfortunately, secondary resistance to these drugs occurs within about one year owing to a T790M gatekeeper mutation. Osimertinib is an irreversible type VI inhibitor that forms a covalent bond with C797 of EGFR and is FDA-approved for the treatment of patients with this mutation; type VI inhibitors generally form a covalent adduct with their target protein. Resistance also develops to this and related type VI inhibitory drugs owing to a C797S mutation; the serine residue is unable to react with the drugs to form a covalent bond. Approximately 20% of breast cancer patients exhibit ErbB2/HER2 gene amplification on chromosome 17q. One of the earliest targeted treatments in cancer involved the development of trastuzumab, a monoclonal antibody that interacts with the extracellular domain ErbB2/HER2 causing its down regulation. Surgery, radiation therapy, chemotherapy with cytotoxic drugs, and hormonal modulation are the mainstays in the treatment of breast cancer. Moreover, lapatinib and neratinib are FDA-approved small molecule ErbB2/HER2 antagonists used in the treatment of selected breast cancer patients. Of the approximate three dozen FDA-approved small molecule protein kinase inhibitors, five are type VI irreversible inhibitors and four of them including afatinib, osimertinib, dacomitinib, and neratinib are directed against the ErbB family of receptors (ibrutinib is the fifth and it targets Bruton tyrosine kinase). Avitinib, olmutinib, and pelitinib are additional type VI inhibitors in clinical trials for non-small cell lung cancer that target EGFR. Secondary resistance to both targeted and cytotoxic drugs is the norm, and devising and implementing strategies for minimizing or overcoming resistance is an important goal in cancer therapeutics.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Bray, F., Ferlay, J., Soerjomataram, I., Siegel, R. L., Torre, L. A., & Jemal, A. (2018) · CA: A Cancer Journal for Clinicians · doi:10.3322/caac.21492 · Cited by 84,109
Siegel, R. L., Miller, K. D., & Jemal, A. (2018) · CA: A Cancer Journal for Clinicians · doi:10.3322/caac.21442 · Cited by 16,579
Lynch, T. J., Bell, D. W., Sordella, R., Gurubhagavatula, S., Okimoto, R. A., Brannigan, B. W., Harris, P. L., Haserlat, S. M., Supko, J. G., Haluska, F. G., et al. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa040938 · Cited by 11,486
EGFR Mutations in Lung Cancer: Correlation with Clinical Response to Gefitinib Therapy
Paez, J. G., Jänne, P. A., Lee, J. C., Tracy, S., Greulich, H., Gabriel, S., Herman, P., Kaye, F. J., Lindeman, N., Boggon, T. J., et al. (2004) · Science · doi:10.1126/science.1099314 · Cited by 9,368
The protein kinase complement of the human genome
Manning, G., Whyte, D. B., Martinez, R., Hunter, T., & Sudarsanam, S. (2002) · Science · doi:10.1126/science.1075762 · Cited by 8,145
Cell Signaling by Receptor Tyrosine Kinases
Lemmon, M. A., & Schlessinger, J. (2010) · Cell · doi:10.1016/j.cell.2010.06.011 · Cited by 7,929
MET Amplification Leads to Gefitinib Resistance in Lung Cancer by Activating ERBB3 Signaling
Engelman, J. A., Zejnullahu, K., Mitsudomi, T., Song, Y., Hyland, C., Park, J. O., Lindeman, N., Gale, C.-M., Zhao, X., Christensen, J., et al. (2007) · Science · doi:10.1126/science.1141478 · Cited by 4,496
Pao, W., Miller, V., Zakowski, M., Doherty, J., Politi, K., Sarkaria, I., Singh, B., Heelan, R., Rusch, V., Fulton, L., et al. (2004) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0405220101 · Cited by 4,338
Moore, M. J., Goldstein, D., Hamm, J., Figer, A., Hecht, J. R., Gallinger, S., Au, H. J., Murawa, P., Walde, D., Wolff, R. A., et al. (2007) · Journal of Clinical Oncology · doi:10.1200/jco.2006.07.9525 · Cited by 3,848
Genotypic and Histological Evolution of Lung Cancers Acquiring Resistance to EGFR Inhibitors
Sequist, L. V., Waltman, B. A., Dias-Santagata, D., Digumarthy, S., Turke, A. B., Fidias, P., Bergethon, K., Shaw, A. T., Gettinger, S., Cosper, A. K., et al. (2011) · Science Translational Medicine · doi:10.1126/scitranslmed.3002003 · Cited by 3,499
Lapatinib plus Capecitabine for HER2-Positive Advanced Breast Cancer
Geyer, C. E., Forster, J., Lindquist, D., Chan, S., Romieu, C. G., Pienkowski, T., Jagiello-Gruszfeld, A., Crown, J., Chan, A., Kaufman, B., et al. (2006) · New England Journal of Medicine · doi:10.1056/nejmoa064320 · Cited by 3,425
Ullrich, A., Coussens, L., Hayflick, J. S., Dull, T. J., Gray, A., Tam, A. W., Lee, J., Yarden, Y., Libermann, T. A., Schlessinger, J., et al. (1984) · Nature · doi:10.1038/309418a0 · Cited by 2,752
Hanks, S. K., & Hunter, T. R. (1995) · PubMed · Cited by 2,518
Herbst, R. S., Heymach, J. V., & Lippman, S. M. (2008) · New England Journal of Medicine · doi:10.1056/nejmra0802714 · Cited by 2,389
The eukaryotic protein kinase superfamily: kinase (catalytic) domain structure and classification 1
Hanks, S. K., & Hunter, T. (1995) · The FASEB Journal · doi:10.1096/fasebj.9.8.7768349 · Cited by 2,318
The T790M mutation in EGFR kinase causes drug resistance by increasing the affinity for ATP
Yun, C.-H., Mengwasser, K. E., Toms, A. V., Woo, M. S., Greulich, H., Wong, K.-K., Meyerson, M., & Eck, M. J. (2008) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0709662105 · Cited by 2,118
AZD9291 in EGFR Inhibitor–Resistant Non–Small-Cell Lung Cancer
Jänne, P. A., Yang, J. C.-H., Kim, D.-W., Planchard, D., Ohe, Y., Ramalingam, S. S., Ahn, M.-J., Kim, S.-W., Su, W.-C., Horn, L., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1411817 · Cited by 2,116
EGF–ERBB signalling: towards the systems level
Citri, A., & Yarden, Y. (2006) · Nature Reviews Molecular Cell Biology · doi:10.1038/nrm1962 · Cited by 2,004
Protein Tyrosine Phosphatases in the Human Genome
Alonso, A., Sasin, J., Bottini, N., Friedberg, I., Friedberg, I., Osterman, A., Godzik, A., Hunter, T., Dixon, J., & Mustelin, T. (2004) · Cell · doi:10.1016/j.cell.2004.05.018 · Cited by 1,886
Knighton, D. R., Zheng, J., Ten Eyck, L. F., Ashford, V. A., Xuong, N.-H., Taylor, S. S., & Sowadski, J. M. (1991) · Science · doi:10.1126/science.1862342 · Cited by 1,759
An allosteric mechanism for activation of the kinase domain of epidermal growth factor receptor
Zhang, X., Gureasko, J., Shen, K., Cole, P. A., & Kuriyan, J. (2006) · Cell · doi:10.1016/j.cell.2006.05.013 · Cited by 1,650
ERK1/2 MAP kinases: Structure, function, and regulation
Roskoski, R. (2012) · Pharmacological Research · doi:10.1016/j.phrs.2012.04.005 · Cited by 1,650
Self-citationCarpenter, G., & Cohen, S. (1990) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(19)38983-5 · Cited by 1,622
Graus-Porta, D. (1997) · The EMBO Journal · doi:10.1093/emboj/16.7.1647 · Cited by 1,590
Thress, K. S., Paweletz, C. P., Felip, E., Cho, B. C., Stetson, D., Dougherty, B., Lai, Z., Markovets, A., Vivancos, A., Kuang, Y., et al. (2015) · Nature Medicine · doi:10.1038/nm.3854 · Cited by 1,589
The ErbB/HER family of protein-tyrosine kinases and cancer
Roskoski, R. (2014) · Pharmacological Research · doi:10.1016/j.phrs.2013.11.002 · Cited by 1,353
Self-citationRequirement for neuregulin receptor erbB2 in neural and cardiac development
Lee, K.-F., Simon, H., Chen, H., Bates, B., Hung, M.-C., & Hauser, C. (1995) · Nature · doi:10.1038/378394a0 · Cited by 1,290
Yun, C.-H., Boggon, T. J., Li, Y., Woo, M. S., Greulich, H., Meyerson, M., & Eck, M. J. (2007) · Cancer Cell · doi:10.1016/j.ccr.2006.12.017 · Cited by 1,192
The neu oncogene: an erb-B-related gene encoding a 185,000-Mr tumour antigen
Schechter, A. L., Stern, D. F., Vaidyanathan, L., Decker, S. J., Drebin, J. A., Greene, M. I., & Weinberg, R. A. (1984) · Nature · doi:10.1038/312513a0 · Cited by 1,175
Aberrant neural and cardiac development in mice lacking the ErbB4 neuregulin receptor
Gassmann, M., Casagranda, F., Orioli, D., Simon, H., Lai, C., Klein, R., & Lemke, G. (1995) · Nature · doi:10.1038/378390a0 · Cited by 1,148
ADAMs: key components in EGFR signalling and development
Blobel, C. P. (2005) · Nature Reviews Molecular Cell Biology · doi:10.1038/nrm1548 · Cited by 1,090
Epithelial immaturity and multiorgan failure in mice lacking epidermal growth factor receptor
Miettinen, P. J., Berger, J. E., Meneses, J., Phung, Y., Pedersen, R. A., Werb, Z., & Derynck, R. (1995) · Nature · doi:10.1038/376337a0 · Cited by 1,039
Tzahar, E., Waterman, H., Chen, X., Levkowitz, G., Karunagaran, D., Lavi, S., Ratzkin, B. J., & Yarden, Y. (1996) · Molecular and Cellular Biology · doi:10.1128/mcb.16.10.5276 · Cited by 1,036
Roskoski, R. (2016) · Pharmacological Research · doi:10.1016/j.phrs.2015.10.021 · Cited by 886
Self-citationActivating HER2 Mutations in HER2 Gene Amplification Negative Breast Cancer
Bose, R., Kavuri, S. M., Searleman, A. C., Shen, W., Shen, D., Koboldt, D. C., Monsey, J., Goel, N., Aronson, A. B., Li, S., et al. (2013) · Cancer Discovery · doi:10.1158/2159-8290.cd-12-0349 · Cited by 868
Solca, F., Dahl, G., Zoephel, A., Bader, G., Sanderson, M., Klein, C., Kraemer, O., Himmelsbach, F., Haaksma, E., & Adolf, G. R. (2012) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.112.197756 · Cited by 865
A native 170,000 epidermal growth factor receptor-kinase complex from shed plasma membrane vesicles.
Cohen, S., Ushiro, H., Stoscheck, C., & Chinkers, M. (1982) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(19)68224-4 · Cited by 776
Pinkas-Kramarski, R., Soussan, L., Waterman, H., Levkowitz, G., Alroy, I., Klapper, L., Lavi, S., Seger, R., Ratzkin, B. J., Sela, M., et al. (1996) · The EMBO Journal · doi:10.1002/j.1460-2075.1996.tb00603.x · Cited by 769
Kornev, A. P., Haste, N. M., Taylor, S. S., & Ten Eyck, L. F. (2006) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0607656103 · Cited by 762
Engelman, J. A., Zejnullahu, K., Gale, C.-M., Lifshits, E., Gonzales, A. J., Shimamura, T., Zhao, F., Vincent, P. W., Naumov, G. N., Bradner, J. E., et al. (2007) · Cancer Research · doi:10.1158/0008-5472.can-07-1885 · Cited by 730
Severe neuropathies in mice with targeted mutations in the ErbB3 receptor
Riethmacher, D., Sonnenberg-Riethmacher, E., Brinkmann, V., Yamaai, T., Lewin, G. R., & Birchmeier, C. (1997) · Nature · doi:10.1038/39593 · Cited by 729
Finlay, M. R. V., Anderton, M., Ashton, S., Ballard, P., Bethel, P. A., Box, M. R., Bradbury, R. H., Brown, S. J., Butterworth, S., Campbell, A., et al. (2014) · Journal of Medicinal Chemistry · doi:10.1021/jm500973a · Cited by 636
Src protein-tyrosine kinase structure, mechanism, and small molecule inhibitors
Roskoski, R. (2015) · Pharmacological Research · doi:10.1016/j.phrs.2015.01.003 · Cited by 607
Self-citationBarker, A. J., Gibson, K. H., Grundy, W., Godfrey, A. A., Barlow, J. J., Healy, M. P., Woodburn, J. R., Ashton, S. E., Curry, B. J., Scarlett, L., et al. (2001) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/s0960-894x(01)00344-4 · Cited by 569
Osimertinib As First-Line Treatment of EGFR Mutation–Positive Advanced Non–Small-Cell Lung Cancer
Ramalingam, S. S., Yang, J. C.-H., Lee, C. K., Kurata, T., Kim, D.-W., John, T., Nogami, N., Ohe, Y., Mann, H., Rukazenkov, Y., et al. (2018) · Journal of Clinical Oncology · doi:10.1200/jco.2017.74.7576 · Cited by 547
A historical overview of protein kinases and their targeted small molecule inhibitors
Roskoski, R. (2015) · Pharmacological Research · doi:10.1016/j.phrs.2015.07.010 · Cited by 526
Self-citationThrough the “Gatekeeper Door”: Exploiting the Active Kinase Conformation
Zuccotto, F., Ardini, E., Casale, E., & Angiolini, M. (2010) · Journal of Medicinal Chemistry · doi:10.1021/jm901443h · Cited by 518
Liao, J. J.-L. (2007) · Journal of Medicinal Chemistry · doi:10.1021/jm0608107 · Cited by 507
United States Food and Drug Administration Drug Approval Summary
Cohen, M. H., Williams, G. A., Sridhara, R., Chen, G., McGuinn, W. D., Morse, D., Abraham, S., Rahman, A., Liang, C., Lostritto, R., et al. (2004) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-03-0564 · Cited by 503
ErbB3/HER3 intracellular domain is competent to bind ATP and catalyze autophosphorylation
Shi, F., Telesco, S. E., Liu, Y., Radhakrishnan, R., & Lemmon, M. A. (2010) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1002753107 · Cited by 471
Aertgeerts, K., Skene, R., Yano, J., Sang, B.-C., Zou, H., Snell, G., Jennings, A., Iwamoto, K., Habuka, N., Hirokawa, A., et al. (2011) · Journal of Biological Chemistry · doi:10.1074/jbc.m110.206193 · Cited by 449
FDA Drug Approval Summary: Erlotinib (Tarceva®) Tablets
Cohen, M. H., Johnson, J. R., Chen, Y.-F., Sridhara, R., & Pazdur, R. (2005) · The Oncologist · doi:10.1634/theoncologist.10-7-461 · Cited by 445
A helix scaffold for the assembly of active protein kinases
Kornev, A. P., Taylor, S. S., & Ten Eyck, L. F. (2008) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0807988105 · Cited by 442
Mok, T. S., Cheng, Y., Zhou, X., Lee, K. H., Nakagawa, K., Niho, S., Lee, M., Linke, R., Rosell, R., Corral, J., et al. (2018) · Journal of Clinical Oncology · doi:10.1200/jco.2018.78.7994 · Cited by 439
Zhao, Z., Wu, H., Wang, L., Liu, Y., Knapp, S., Liu, Q., & Gray, N. S. (2014) · ACS Chemical Biology · doi:10.1021/cb500129t · Cited by 433
Treatment of Non–Small-Cell Lung Cancer with Erlotinib or Gefitinib
Cataldo, V. D., Gibbons, D. L., Pérez-Soler, R., & Quintás-Cardama, A. (2011) · New England Journal of Medicine · doi:10.1056/nejmct0807960 · Cited by 418
Shah, K., Liu, Y., Deirmengian, C., & Shokat, K. M. (1997) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.94.8.3565 · Cited by 417
The Evolution of Protein Kinase Inhibitors from Antagonists to Agonists of Cellular Signaling
Dar, A. C., & Shokat, K. M. (2011) · Annual Review of Biochemistry · doi:10.1146/annurev-biochem-090308-173656 · Cited by 388
RAF protein-serine/threonine kinases: Structure and regulation
Roskoski, R. (2010) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2010.07.092 · Cited by 376
Self-citationJanus kinase (JAK) inhibitors in the treatment of inflammatory and neoplastic diseases
Roskoski, R. (2016) · Pharmacological Research · doi:10.1016/j.phrs.2016.07.038 · Cited by 373
Self-citationTen things you should know about protein kinases: IUPHAR R eview 14
Fabbro, D., Cowan‐Jacob, S. W., & Moebitz, H. (2015) · British Journal of Pharmacology · doi:10.1111/bph.13096 · Cited by 347
Afatinib: First Global Approval
Dungo, R. T., & Keating, G. M. (2013) · Drugs · doi:10.1007/s40265-013-0111-6 · Cited by 329
Steroid-hormone receptors in breast cancer
Wittliff, J. L. (1984) · Cancer · doi:10.1002/1097-0142(19840201)53:3+<630::aid-cncr2820531308>3.0.co;2-3 · Cited by 325
Making the first move in EGFR-driven or ALK-driven NSCLC: first-generation or next-generation TKI?
Recondo, G., Facchinetti, F., Olaussen, K. A., Besse, B., & Friboulet, L. (2018) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-018-0081-4 · Cited by 321
Anaplastic lymphoma kinase (ALK): Structure, oncogenic activation, and pharmacological inhibition
Roskoski, R. (2013) · Pharmacological Research · doi:10.1016/j.phrs.2012.11.007 · Cited by 303
Self-citationTsou, H.-R., Overbeek-Klumpers, E. G., Hallett, W. A., Reich, M. F., Floyd, M. B., Johnson, B. D., Michalak, R. S., Nilakantan, R., Discafani, C., Golas, J., et al. (2005) · Journal of Medicinal Chemistry · doi:10.1021/jm040159c · Cited by 301
KLIFS: A Knowledge-Based Structural Database To Navigate Kinase–Ligand Interaction Space
van Linden, O. P. J., Kooistra, A. J., Leurs, R., de Esch, I. J. P., & de Graaf, C. (2014) · Journal of Medicinal Chemistry · doi:10.1021/jm400378w · Cited by 298
Winer, E., Gralow, J., Diller, L., Karlan, B., Loehrer, P., Pierce, L., Demetri, G., Ganz, P., Kramer, B., Kris, M., et al. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2008.21.2134 · Cited by 293
Cardiotoxicity induced by tyrosine kinase inhibitors
Orphanos, G. S., Ioannidis, G. N., & Ardavanis, A. G. (2009) · Acta Oncologica · doi:10.1080/02841860903229124 · Cited by 284
Progress in adjuvant systemic therapy for breast cancer
Pondé, N. F., Zardavas, D., & Piccart, M. (2019) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-018-0089-9 · Cited by 281
Emerging roles of ADAM and ADAMTS metalloproteinases in cancer
Rocks, N., Paulissen, G., El Hour, M., Quesada, F., Crahay, C., Gueders, M., Foidart, J. M., Noel, A., & Cataldo, D. (2008) · Biochimie · doi:10.1016/j.biochi.2007.08.008 · Cited by 266
Wissner, A., Overbeek, E., Reich, M. F., Floyd, M. B., Johnson, B. D., Mamuya, N., Rosfjord, E. C., Discafani, C., Davis, R., Shi, X., et al. (2003) · Journal of Medicinal Chemistry · doi:10.1021/jm020241c · Cited by 264
Roskoski, R. (2017) · Pharmacological Research · doi:10.1016/j.phrs.2017.03.010 · Cited by 260
Self-citationVijayan, R. S. K., He, P., Modi, V., Duong-Ly, K. C., Ma, H., Peterson, J. R., Dunbrack, R. L., & Levy, R. M. (2015) · Journal of Medicinal Chemistry · doi:10.1021/jm501603h · Cited by 245
The Neuregulin-I/ErbB Signaling System in Development and Disease
(2007) · Advances in Anatomy Embryology and Cell Biology · doi:10.1007/978-3-540-37107-6 · Cited by 243
Cyclin-dependent protein kinase inhibitors including palbociclib as anticancer drugs
Roskoski, R. (2016) · Pharmacological Research · doi:10.1016/j.phrs.2016.03.012 · Cited by 237
Self-citationEvolution of the eukaryotic protein kinases as dynamic molecular switches
Taylor, S. S., Keshwani, M. M., Steichen, J. M., & Kornev, A. P. (2012) · Philosophical Transactions of the Royal Society B: Biological Sciences · doi:10.1098/rstb.2012.0054 · Cited by 233
Trastuzumab Has Preferential Activity against Breast Cancers Driven by HER2 Homodimers
Ghosh, R., Narasanna, A., Wang, S. E., Liu, S., Chakrabarty, A., Balko, J. M., González-Angulo, A. M., Mills, G. B., Penuel, E., Winslow, J., et al. (2011) · Cancer Research · doi:10.1158/0008-5472.can-10-1872 · Cited by 228
ErbB/HER protein-tyrosine kinases: Structures and small molecule inhibitors
Roskoski, R. (2014) · Pharmacological Research · doi:10.1016/j.phrs.2014.06.001 · Cited by 218
Self-citationA Novel Juxtamembrane Domain Isoform of HER4/ErbB4
Elenius, K., Corfas, G., Paul, S., Choi, C. J., Rio, C., Plowman, G. D., & Klagsbrun, M. (1997) · Journal of Biological Chemistry · doi:10.1074/jbc.272.42.26761 · Cited by 214
Deciphering the Structural Basis of Eukaryotic Protein Kinase Regulation
Meharena, H. S., Chang, P., Keshwani, M. M., Oruganty, K., Nene, A. K., Kannan, N., Taylor, S. S., & Kornev, A. P. (2013) · PLoS Biology · doi:10.1371/journal.pbio.1001680 · Cited by 208
PKIDB: A Curated, Annotated and Updated Database of Protein Kinase Inhibitors in Clinical Trials
Carles, F., Bourg, S., Meyer, C., & Bonnet, P. (2018) · Molecules · doi:10.3390/molecules23040908 · Cited by 197
Targeting oncogenic Raf protein-serine/threonine kinases in human cancers
Roskoski, R. (2018) · Pharmacological Research · doi:10.1016/j.phrs.2018.08.013 · Cited by 194
Self-citationTaylor, S. S., Radzio‐Andzelm, E., & Hunter, T. (1995) · The FASEB Journal · doi:10.1096/fasebj.9.13.7557015 · Cited by 188
Approaches to discover non-ATP site kinase inhibitors
Gavrin, L. K., & Saiah, E. (2013) · MedChemComm · doi:10.1039/c2md20180a · Cited by 184
New Directions in Targeting Protein Kinases: Focusing Upon True Allosteric and Bivalent Inhibitors
Lamba, V., & Ghosh, I. (2012) · Current Pharmaceutical Design · doi:10.2174/138161212800672813 · Cited by 182
Lu, X., Yu, L., Zhang, Z., Ren, X., Smaill, J. B., & Ding, K. (2018) · Medicinal Research Reviews · doi:10.1002/med.21488 · Cited by 173
Roskoski, R. (2018) · Pharmacological Research · doi:10.1016/j.phrs.2018.01.021 · Cited by 170
Self-citationNeratinib overcomes trastuzumab resistance in HER2 amplified breast cancer
Canonici, A., Gijsen, M., Mullooly, M., Bennett, R., Bouguern, N., Pedersen, K., O’Brien, N. A., Roxanis, I., Li, J.-L., Bridge, E., et al. (2013) · Oncotarget · doi:10.18632/oncotarget.1148 · Cited by 164
Binding mode of the breakthrough inhibitor AZD9291 to epidermal growth factor receptor revealed
Yosaatmadja, Y., Silva, S., Dickson, J. M. J. J., Patterson, A. V., Smaill, J. B., Flanagan, J. U., McKeage, M. J., & Squire, C. J. (2015) · Journal of Structural Biology · doi:10.1016/j.jsb.2015.10.018 · Cited by 157
A molecular gate which controls unnatural ATP analogue recognition by the tyrosine kinase v-Src
Liu, Y., Shah, K., Yang, F., Witucki, L. A., & Shokat, K. M. (1998) · Bioorganic & Medicinal Chemistry · doi:10.1016/s0968-0896(98)00099-6 · Cited by 156
Clinical outcomes in non‐small‐cell lung cancer patients with EGFR mutations: pooled analysis
Paz-Ares, L. G., Soulières, D., Melezínek, I., Moecks, J., Keil, L., Mok, T. S. K., Rosell, R., & Klughammer, B. (2010) · Journal of Cellular and Molecular Medicine · doi:10.1111/j.1582-4934.2009.00991.x · Cited by 154
Mechanism for activation of mutated epidermal growth factor receptors in lung cancer
Brewer, M. R., Yun, C., Lai, D., Lemmon, M. A., Eck, M. J., & Pao, W. J. (2013) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1220050110 · Cited by 154
Erlichman, C., Hidalgo, M. M., Boni, J. P., Martins, P., Quinn, S., Zacharchuk, C., Amorusi, P., Adjei, A. A., & Rowinsky, E. K. (2006) · Journal of Clinical Oncology · doi:10.1200/jco.2005.01.8960 · Cited by 153
Neratinib: First Global Approval
Deeks, E. D. (2017) · Drugs · doi:10.1007/s40265-017-0811-4 · Cited by 148
Treatment of advanced HER2-positive breast cancer: 2018 and beyond
Ponde, N. F., Brandão, M., El-Hachem, G., Werbrouck, E., & Piccart, M. J. (2018) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2018.04.016 · Cited by 143
Roskoski, R. J. (2017) · Pharmacological Research · doi:10.1016/j.phrs.2017.04.022 · Cited by 138
Self-citationAnaplastic lymphoma kinase (ALK) inhibitors in the treatment of ALK-driven lung cancers
Roskoski, R. J. (2017) · Pharmacological Research · doi:10.1016/j.phrs.2017.01.007 · Cited by 133
Self-citationGotoh, N., Tojo, A., Hino, M., Yazaki, Y., & Shibuya, M. (1992) · Biochemical and Biophysical Research Communications · doi:10.1016/0006-291x(92)90812-y · Cited by 126
Roskoski, R. J. (2016) · Pharmacological Research · doi:10.1016/j.phrs.2016.12.009 · Cited by 119
Self-citationRole of RET protein-tyrosine kinase inhibitors in the treatment RET-driven thyroid and lung cancers
Roskoski, R. J., & Sadeghi‐Nejad, A. (2017) · Pharmacological Research · doi:10.1016/j.phrs.2017.12.021 · Cited by 114
Self-citationGuidelines for preparing color figures for everyone including the colorblind
Roskoski, R. J. (2017) · Pharmacological Research · doi:10.1016/j.phrs.2017.02.005 · Cited by 112
Self-citationMassarelli, E., Johnson, F. M., Erickson, H. S., Wistuba, I. I., & Papadimitrakopoulou, V. (2013) · Lung Cancer · doi:10.1016/j.lungcan.2013.01.018 · Cited by 110
Redefining the Protein Kinase Conformational Space with Machine Learning
Ung, P. M. U., Rahman, R., & Schlessinger, A. (2018) · Cell chemical biology · doi:10.1016/j.chembiol.2018.05.002 · Cited by 104
Treating Patients With EGFR-Sensitizing Mutations: First Line or Second Line—Is There a Difference?
Mok, T., Yang, J.-J., & Lam, K.-C. (2013) · Journal of Clinical Oncology · doi:10.1200/jco.2012.43.0652 · Cited by 103
Singh, H., Walker, A. J., Amiri-Kordestani, L., Cheng, J., Tang, S., Balcazar, P., Barnett-Ringgold, K., Palmby, T. R., Cao, X., Zheng, N., et al. (2018) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-17-3628 · Cited by 99
The Type 1 growth factor receptors and their ligands considered as a complex system.
Gullick, W. J. (2001) · Endocrine Related Cancer · doi:10.1677/erc.0.0080075 · Cited by 97
Larionov, A. A. (2018) · Frontiers in Oncology · doi:10.3389/fonc.2018.00089 · Cited by 96
Structure-based Virtual Screening Approaches in Kinase-directed Drug Discovery
Bajusz, D., Ferenczy, G. G., & Keserű, G. M. (2017) · Current Topics in Medicinal Chemistry · doi:10.2174/1568026617666170224121313 · Cited by 88
Xu, X., Mao, L., Xu, W., Tang, W., Zhang, X., Xi, B., Xu, R., Fang, X., Liu, J., Fang, C., et al. (2016) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-16-0281 · Cited by 87
Approved and Experimental Small‐Molecule Oncology Kinase Inhibitor Drugs: A Mid‐2016 Overview
Fischer, P. M. (2016) · Medicinal Research Reviews · doi:10.1002/med.21409 · Cited by 84
Participation of ADP Dissociation in the Rate-Determining Step in cAMP-Dependent Protein Kinase
Zhou, J., & Adams, J. A. (1997) · Biochemistry · doi:10.1021/bi971438n · Cited by 83
Kobayashi, Y., Azuma, K., Nagai, H., Kim, Y. H., Togashi, Y., Sesumi, Y., Chiba, M., Shimoji, M., Sato, K., Tomizawa, K., et al. (2016) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-16-0407 · Cited by 82
Roskoski, R. J. (2018) · Pharmacological Research · doi:10.1016/j.phrs.2018.04.020 · Cited by 80
Self-citationThe Under-Appreciated Promiscuity of the Epidermal Growth Factor Receptor Family
Kennedy, S. P., Hastings, J. F., Han, J. Z. R., & Croucher, D. R. (2016) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2016.00088 · Cited by 77
Targeting EGFR T790M mutation in NSCLC: From biology to evaluation and treatment
Passaro, A., Guerini‐Rocco, E., Pochesci, A., Vacirca, D., Spitaleri, G., Catania, C., Rappa, A., Barberis, M. C. P., & de Marinis, F. (2017) · Pharmacological Research · doi:10.1016/j.phrs.2017.01.003 · Cited by 76
Kwarcinski, F. E., Brandvold, K. R., Phadke, S., Beleh, O. M., Johnson, T. K., Meagher, J. L., Seeliger, M. A., Stuckey, J. A., & Soellner, M. B. (2016) · ACS Chemical Biology · doi:10.1021/acschembio.5b01018 · Cited by 75
EGFR T790M and C797S Mutations as Mechanisms of Acquired Resistance to Dacomitinib
Kobayashi, Y., Fujino, T., Nishino, M., Koga, T., Chiba, M., Sesumi, Y., Ohara, S., Shimoji, M., Tomizawa, K., Takemoto, T., et al. (2018) · Journal of Thoracic Oncology · doi:10.1016/j.jtho.2018.01.009 · Cited by 65
Smaill, J. B., Gonzales, A. J., Spicer, J. A., Lee, H., Reed, J. E., Sexton, K., Althaus, I. W., Zhu, T., Black, S. L., Blaser, A., et al. (2016) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.6b00883 · Cited by 63
Ma, Y., Zheng, X. X., Zhao, H., Fang, W., Zhang, Y., Ge, J., Wang, L., Wang, W., Jiang, J., Chuai, S., et al. (2018) · Journal of Thoracic Oncology · doi:10.1016/j.jtho.2018.03.025 · Cited by 58
Mutation spectra of RAS gene family in colorectal cancer
Chang, Y.-Y., Lin, P.-C., Lin, H., Lin, J.-K., Chen, W.-S., Jiang, J., Yang, S.-H., Liang, W.-Y., & Chang, S. (2016) · The American Journal of Surgery · doi:10.1016/j.amjsurg.2016.02.013 · Cited by 56
Hochmair, M. J. (2018) · Targeted Oncology · doi:10.1007/s11523-018-0566-1 · Cited by 56
Docetaxel/anthracycline combinations for breast cancer treatment
von Minckwitz, G. (2007) · Expert Opinion on Pharmacotherapy · doi:10.1517/14656566.8.4.485 · Cited by 50
Malapelle, U., Ricciuti, B., Baglivo, S., Pepe, F., Pisapia, P., Anastasi, P., Tazza, M., Sidoni, A., Liberati, A. M., Bellezza, G., et al. (2018) · Recent results in cancer research/Recent Results in Cancer Research · doi:10.1007/978-3-319-91442-8_18 · Cited by 46
Cardiac ErbB-1/ErbB-2 mutant expression in young adult mice leads to cardiac dysfunction
Rajagopalan, V., Zucker, I. H., Jones, J. A., Carlson, M., & Ma, Y. J. (2008) · American Journal of Physiology-Heart and Circulatory Physiology · doi:10.1152/ajpheart.91436.2007 · Cited by 42
Debiasi, M., Polanczyk, C. A., Ziegelmann, P. K., Barrios, C. H., Cao, H., Dignam, J. J., Goss, P. E., Bychkovsky, B., Finkelstein, D. M., Guindalini, R. S. C., et al. (2018) · Frontiers in Oncology · doi:10.3389/fonc.2018.00156 · Cited by 39
Frame, M. C., & Roskoski, R. J. (2016) · Elsevier eBooks · doi:10.1016/b978-0-12-809633-8.07199-5 · Cited by 32
Self-citationJiang, N., Lin, J., Wang, J., Zhang, B., Li, A., Chen, Z., Guo, S., Li, B., Duan, Y., Yan, R., et al. (2018) · Experimental and Therapeutic Medicine · doi:10.3892/etm.2018.6459 · Cited by 30
Kinase-Centric Computational Drug Development
Kooistra, A. J., & Volkamer, A. (2017) · Annual reports in medicinal chemistry · doi:10.1016/bs.armc.2017.08.001 · Cited by 29
Dacomitinib in lung cancer: a “lost generation” EGFR tyrosine-kinase inhibitor from a bygone era?
Ou, S.-H., & Soo, R. (2015) · Drug Design, Development and Therapy · doi:10.2147/dddt.s52787 · Cited by 28
Dong, L., Lei, D., & Zhang, H. (2017) · Oncotarget · doi:10.18632/oncotarget.19925 · Cited by 25
Colorectal cancer genomics and designing rational trials
Mondaca, S., & Yaeger, R. D. (2018) · Annals of Translational Medicine · doi:10.21037/atm.2018.03.27 · Cited by 23
Abdallah, S. M.-B., & Hirsh, V. (2018) · Current Oncology · doi:10.3747/co.25.3732 · Cited by 20
Cited by
Small molecules in targeted cancer therapy: advances, challenges, and future perspectives
Zhong, L., Li, Y., Xiong, L., Wang, W., Wu, M., Yuan, T., Yang, W., Tian, C., Miao, Z., Wang, T., et al. (2021) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-021-00572-w · Cited by 1,696
Comprehensive review of targeted therapy for colorectal cancer
Xie, Y.-H., Chen, Y.-X., & Fang, J.-Y. (2020) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-020-0116-z · Cited by 1,687
Properties of FDA-approved small molecule protein kinase inhibitors: A 2020 update
Roskoski, R. (2020) · Pharmacological Research · doi:10.1016/j.phrs.2019.104609 · Cited by 559
Self-citationProperties of FDA-approved small molecule protein kinase inhibitors
Roskoski, R. (2019) · Pharmacological Research · doi:10.1016/j.phrs.2019.03.006 · Cited by 554
Self-citationMolecular Mechanisms of Colon Cancer Progression and Metastasis: Recent Insights and Advancements
Malki, A., ElRuz, R. A., Gupta, I., Allouch, A., Vranic, S., & Al Moustafa, A.-E. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms22010130 · Cited by 398
Metadata
- Authors
- Roskoski, R.
- Venue
- Pharmacological Research
- Publisher
- Elsevier BV
- Published
- 2019-01
- Volume
- 139
- Pages
- 395-411
- ISSN
- 1043-6618 (ISSN-L)
- OpenAlex
- W2903084459
- Cited by
- 487
- References
- 133
- FWCI
- 15.92
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.